Effect of egg white protein and zinc-enriched synbiotic supplement in Sarcopenic Elderly

Comparison of the effectiveness of the egg white protein and zinc-enriched synbiotic supplement and placebo on the muscle strength, muscle mass and quality of life in older adults with sarcopenia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220414054536N1

Enrollment

Registered

2022-06-06

Start date

2022-04-20

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia. Sarcopenia

Interventions

Intervention 1: Intervention group: Receiving egg white protein (Gol Powder Golestan Co, Iran) and zinc (Zahravi Pharm Co, Iran)-enriched synbiotic (Pardis Roshd Mehregan Co, Iran) powder daily for 8

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Inclusion criteria

Inclusion criteria: Men and women aged 65 years and older Sarcopenia diagnosis according to European Working Group on Sarcopenia in Older People (EWGSOP) guidelines using calcium and vitamin D supplements

Exclusion criteria

Exclusion criteria: Subjects with history of chronic disease (e.g. Congestive Heart Failure (CHF), Chronic Obstructive Pulmonary Disorder (COPD), Chronic Renal Failure (CRF), cirrhosis liver failure and active cancer. Subjects with history of uncontrolled diabetes and stroke.

Design outcomes

Primary

Measure	Time frame
Hand grip Strength. Timepoint: Baseline and End-of-trial. Method of measurement: Hydraulic Hand Dynamometer.;Lean body mass. Timepoint: Baseline and End-of-trial. Method of measurement: Dual energy X-ray Absorptiometry (DXA).	—

Secondary

Measure	Time frame
Appendicular Skeletal Muscle Mass. Timepoint: Baseline and End-of-trial. Method of measurement: Dual energy X-ray Absorptiometry (DXA).;Weight. Timepoint: Baseline and End-of-trial. Method of measurement: Standardized methods.;BMI. Timepoint: Baseline and End-of-trial. Method of measurement: Standardized methods.;Waist circumference. Timepoint: Baseline and End-of-trial. Method of measurement: Standardized methods.;Calf circumference. Timepoint: Baseline and End-of-trial. Method of measurement: Standardized methods.;Arm circumference. Timepoint: Baseline and End-of-trial. Method of measurement: Standardized methods.;Fat mass. Timepoint: Baseline and End-of-trial. Method of measurement: Dual energy X-ray Absorptiometry (DXA).;Gynoid fat mass. Timepoint: Baseline and End-of-trial. Method of measurement: Dual energy X-ray Absorptiometry (DXA).;Android fat mass. Timepoint: Baseline and End-of-trial. Method of measurement: Dual energy X-ray Absorptiometry (DXA).;Physical performance. Timepoint: Baseline and End-of-trial. Method of measurement: The Short Physical Performance Battery (SPPB) score.;Quality of life. Timepoint: Baseline and End-of-trial. Method of measurement: The Short Form Health Survey-36 (SF-36) questionnaire and sarcopenia specific quality of life questionnaire (SarQoL®-IR).;Percent of fat. Timepoint: Baseline and End-of-trial. Method of measurement: Dual energy X-ray Absorptiometry (DXA).;Fasting Blood Sugar (FBS) level. Timepoint: Baseline and End-of-trial. Method of measurement: Auto analyser.;Lipid profile (LDL, HDL, Triglyceride, total cholesterol). Timepoint: Baseline and End-of-trial. Method of measurement: Chemical method (kit).	—

Measure

Time frame

Appendicular Skeletal Muscle Mass. Timepoint: Baseline and End-of-trial. Method of measurement: Dual energy X-ray Absorptiometry (DXA).;Weight. Timepoint: Baseline and End-of-trial. Method of measurement: Standardized methods.;BMI. Timepoint: Baseline and End-of-trial. Method of measurement: Standardized methods.;Waist circumference. Timepoint: Baseline and End-of-trial. Method of measurement: Standardized methods.;Calf circumference. Timepoint: Baseline and End-of-trial. Method of measurement: Standardized methods.;Arm circumference. Timepoint: Baseline and End-of-trial. Method of measurement: Standardized methods.;Fat mass. Timepoint: Baseline and End-of-trial. Method of measurement: Dual energy X-ray Absorptiometry (DXA).;Gynoid fat mass. Timepoint: Baseline and End-of-trial. Method of measurement: Dual energy X-ray Absorptiometry (DXA).;Android fat mass. Timepoint: Baseline and End-of-trial. Method of measurement: Dual energy X-ray Absorptiometry (DXA).;Physical performance. Timepoint: Baseline and End-of-trial. Method of measurement: The Short Physical Performance Battery (SPPB) score.;Quality of life. Timepoint: Baseline and End-of-trial. Method of measurement: The Short Form Health Survey-36 (SF-36) questionnaire and sarcopenia specific quality of life questionnaire (SarQoL®-IR).;Percent of fat. Timepoint: Baseline and End-of-trial. Method of measurement: Dual energy X-ray Absorptiometry (DXA).;Fasting Blood Sugar (FBS) level. Timepoint: Baseline and End-of-trial. Method of measurement: Auto analyser.;Lipid profile (LDL, HDL, Triglyceride, total cholesterol). Timepoint: Baseline and End-of-trial. Method of measurement: Chemical method (kit).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Hossein Dabbaghmanesh

Shiraz University of Medical Sciences

dabbaghmanesh@gmail.com+98 71 3235 7282

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026